

**Ramot at Tel Aviv University Ltd. Announces Licensing Agreement with
Dexcel Pharma Technologies Ltd.**

*Under the agreement, a new therapeutic strategy for Parkinson's disease will be developed
using a naturally occurring-peptide*

Tel Aviv, Israel (July 28, 2015) Ramot at Tel Aviv University Ltd., Tel Aviv University's Tech transfer company, has signed an exclusive licensing agreement with Dexcel Pharma Technologies Ltd. for the development and commercialization of a new therapeutic strategy for Parkinson's disease, developed at the university.

Based on the identification of new beta-synuclein recognition modules, the technology is a novel approach to inhibiting alpha-synuclein aggregation, a hallmark of Parkinson's disease. This disease-modifying treatment may enable inhibition of disease progression, in contrast to current symptomatic therapy that does not arrest disease progression.

The technology was developed by Dr. Ronit Shaltiel-Karyo and Prof. Ehud Gazit from the Department of Molecular Microbiology and Biotechnology, the George S. Wise Faculty of Life Sciences at Tel Aviv University. Research at the Gazit lab focuses on the study of biomolecular self-assembly. Shaltiel-Karyo's PhD thesis resulted in the identification of minimal recognition elements that facilitate the assembly of amyloid fibrils and identified novel ways to inhibit this process.

" Ramot is very pleased to have forged this licensing agreement between outstanding researchers and a leading international pharma company, which promises to bring benefit to millions of Parkinson's sufferers worldwide," states Mr. Shlomo Nimrodi, the CEO of Ramot.

"Dexcel is very excited to develop a novel drug inhibiting alpha-synuclein aggregation with the potential to modify disease progression in Parkinson's patients. The collaboration with Ramot on this program marks another example of Dexcel's dedication to investment in innovative R&D " said Ilan Oren, VP of Business Development at Dexcel Pharma.

Parkinson's disease (PD) is a chronic, progressive ailment caused by neurodegeneration and a decreased concentration of dopamine in the brain, ultimately leading to the brain's inability to control the body's movements. PD is one of the most common neurological disorders, and its global prevalence is projected to grow to upwards of six million cases worldwide by 2022. Through advances in technology and drug development, the treatment market for movement disorder syndromes such as Parkinson's disease is forecasted to grow to \$21 billion in global sales by 2020 (<http://parkinsons.conferenceseries.com/>).

About Dexcel Pharma

Dexcel Pharma is a private international specialty pharmaceutical company focused on the development, manufacture and commercialization of value-adding drugs. Dexcel Pharma has a diversified commercial portfolio of branded and generic drugs sold in more than 30 countries worldwide and a rich pipeline of new developments, novel formulations and complex generics. Dexcel Pharma is headquartered in Israel and has ~ 1,000 employees worldwide.

Company Contact:

Ilan Oren

VP, Business Development

Dexcel Pharma Technologies, Ltd.

E. ilan.oren@dexcel.com

About Ramot at Tel Aviv University

Ramot is the technology transfer company of Tel Aviv University. Ramot fosters, initiates, leads, and manages the transfer of new technologies from university laboratories to the marketplace by performing all activities relating to the protection and commercialization of inventions and discoveries made by faculty, students and other researchers. Ramot provides a dynamic interface connecting industry to leading-edge science and innovation, offering new business opportunities in a broad range of emerging markets .

For more information, visit www.ramot.org.

Ramot Contact:

Maya Kotler

Marketing Manager

RAMOT at Tel Aviv University Ltd.

E. maya.kotler@ramot.org

P. +972.3.6405062